US EditionPublished • loading... • Updated
Abbvie's Latest Acquisition Targets Gilgamesh's Psychedelic Drug to Treat Depression
AbbVie will pay up to $1.2 billion to acquire bretisilocin, a psychedelic drug showing significant antidepressant effects in Phase 2 trials for major depressive disorder.
- AbbVie said on Monday it will acquire Gilgamesh Pharmaceuticals' lead antidepressant bretisilocin for up to $1.2 billion, announced from North Chicago, Illinois and New York.
- Amid nearly 300 million people living with depression, AbbVie's purchase builds on a 2024 collaboration and reflects its focus on expanding psychiatric treatment options.
- Recent Phase 2a data showed bretisilocin achieved an 18.5-point reduction in MADRS at 24 hours and a-21.6 change at Day 14 versus-12.1 for a low-dose comparator.
- AbbVie plans to advance bretisilocin toward late-stage clinical development while Gilgamesh will spin off Gilgamesh Pharma Inc. to retain staff and other programs, positioning AbbVie at the forefront of psychiatric care.
- The deal underscores growing Big Pharma interest in psychedelics, as firms invest billions in next-generation psychedelic therapies despite last year's Cerevel Therapeutics trial failure.
Insights by Ground AI
12 Articles
12 Articles
AbbVie to Buy Gilgamesh Depression Drug for Up to $1.2 Billion
AbbVie Inc. agreed to buy an experimental depression treatment from Gilgamesh Pharmaceuticals Inc. for up to $1.2 billion in a deal that highlights the drug industry’s growing interest in next-generation psychedelic compounds.
·United States
Read Full Article
AbbVie Embraces Psychedelic Drug with Up-to-$1.2B Deal for Gilgamesh's MDD Candidate
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to $1.2 billion—a deal that, according to one analyst, reflects growing interest in psychedelic drugs by biopharma giants. Bretisilocin, also called GM-2505, is a 5-HT2A receptor agonist and 5-HT releaser for which Gilgamesh in May announced positive topl…
Coverage Details
Total News Sources12
Leaning Left2Leaning Right0Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 40%
C 60%
Factuality
To view factuality data please Upgrade to Premium
